Home Newsfeeds Evercore ISI Group Reinstates Outperform on Tidewater, Announces $42 Price Target

Evercore ISI Group Reinstates Outperform on Tidewater, Announces $42 Price Target

Evercore ISI Group analyst James West reinstates Tidewater (NYSE:TDW) with a Outperform and announces $42 price target.

byBenzinga Newsdesk

September 6, 2022

1 minute read

Evercore ISI Group analyst James West reinstates Tidewater (NYSE:TDW) with a Outperform and announces $42 price target.

Halliburton Clocks 31% Revenue Growth In Q4 Backed By Strong Segmental Performance; Boosts Quarterly Dividend

By Anusuya Lahiri

January 24, 8:45 AM

Halliburton Company (NYSE:HAL), a provider of products and services to the energy industry, reported fourth-quarter FY22 revenue growth of…

HAL

springbig Enters Into An Exclusive Partnership With Subscription-Based Service Kind+

By Vuk Zdinjak

July 6, 7:37 AM

springbig (NASDAQ: SBIG) (NASDAQ: SBIGW), a leading provider of SaaS-based marketing solutions, consumer mobile app experiences, and omnichannel loyalty programs to the cannabis industry, entered into an exclusive partners

SBIG

Nvidia To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday

By Avi Kapoor

June 4, 8:20 AM

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst…

ADSK

Dyadic Announced An MoU With Bangladesh’s State-Owned Pharmaceutical Company To Facilitate Biopharmaceutical Research And Biomanufacturing Capacity

By Happy Mohamed

June 21, 8:34 AM

Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on building innovative microbial

DYAI

Evercore ISI Group Reinstates Outperform on Tidewater, Announces $42 Price Target

Related Posts

Halliburton Clocks 31% Revenue Growth In Q4 Backed By Strong Segmental Performance; Boosts Quarterly Dividend

springbig Enters Into An Exclusive Partnership With Subscription-Based Service Kind+

Nvidia To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday

Dyadic Announced An MoU With Bangladesh’s State-Owned Pharmaceutical Company To Facilitate Biopharmaceutical Research And Biomanufacturing Capacity